|
| . |
| AMORYN increases levels of four neurotransmitters: AMORYN acts through three distinct mechanisms: |
AMORYN Delivers a Broad Spectrum of Neurochemical Action The factors contributing to depression can be complex, and will differ for every person. AMORYN addresses this fact by providing a broad spectrum of action within the CNS. By enhancing many mood-related pathways at multiple levels of function, AMORYN may provide more balanced emotional support with fewer side effects than other options. AMORYN acts upon all four of the neural pathways - serotonergic, dopaminergic, noradrenergic, and GABAergic - critical to the regulation of mood. Most prescription antidepressants affect only one or two of these pathways. As a result, they may address the disorder incompletely for many people and not at all for others. AMORYN provides multiple levels of support - synaptic, metabolic and nutritional - for each of these systems. Levels of many neurotransmitters - serotonin (5HT), dopamine (DA), norepinephrine (NE), and GABA - are increased through multiple actions. The hyperforin in AMORYN acts as a reuptake inhibitor of 5HT, DA, NE, and GABA. But AMROYN goes beyond synthetic reuptake inhibitors by providing 5-HTP, the direct metabolic precursor to serotonin. And the nutritional co-factors in AMORYN - B6, B12 and Folic Acid - facilitate increased production of 5-HT, DA and NE by enabling the CNS to produce extra SAM-e. Deficiencies of B6, B12 and Folic Acid, as well as low levels of SAM-e, are common in depressed patients and can prevent the maintenance of healthy neurochemical balance. Thus, activation of serotonergic, dopaminergic, noradrenergic and GABAergic circuits is enhanced at multiple points. AMORYN increases the amount of neurotransmitter available for release into the synapse and, at the same time, decreases the reuptake of neurotransmitter from the synapse. No other dietary supplement or prescription medication provides this broad spectrum of action. This broad spectrum of action allows AMORYN to achieve unsurpassed real-world success rates. For additional information, review the clinical research or learn more about the quality-control procedures followed when manufacturing AMORYN. |
         |
|
